{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:32:09Z","timestamp":1787671929954,"version":"build-2736575974"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone metastasis remains a serious threat to breast cancer patients. This condition arises from the outgrowth of previously dormant tumour cells in this site. Dormant tumour cells are almost impossible to detect in human patents, and these cells acquire \u201cstem like\u201d characteristics rendering them resistant to current cancer therapies. Furthermore, the development of therapies to target this population has proved challenging. The bone marrow is a particularly permissive environment for tumour cell dissemination and dormancy, but the mechanisms regulating this process remain to be completely elucidated. Expansion of our understanding of the mechanisms underlying tumour dormancy is critical to the development of targeted therapies and thus, the prevention, or treatment, of metastatic disease. This review aims to explore mechanisms of tumour dormancy in bone, in detail, focusing specifically on breast cancer dormancy. In addition to subsequent discussion of traditional and new, state of the art, methods of studying dormancy to aid further research efforts.<\/jats:p>","DOI":"10.1007\/s10585-026-10412-2","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:05:09Z","timestamp":1780473909000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of breast cancer dormancy in bone metastasis"],"prefix":"10.1007","volume":"43","author":[{"given":"Maria L.","family":"Price","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Le Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis A.","family":"Quayle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope D.","family":"Ottewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"10412_CR1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1203543","volume":"331","author":"CL Chaffer","year":"2011","unstructured":"Chaffer CL, Weinberg RA (2011) A perspective on cancer cell metastasis. Science 331:1559\u20131564","journal-title":"Science"},{"key":"10412_CR2","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.3390\/ijms20246158","volume":"20","author":"CM Neophytou","year":"2019","unstructured":"Neophytou CM, Kyriakou TC, Papageorgis P (2019) Mechanisms of metastatic tumor dormancy and implications for cancer therapy. Int J Mol Sci 20:6158","journal-title":"Int J Mol Sci"},{"key":"10412_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20120401","volume":"445","author":"F Oeztuerk-Winder","year":"2012","unstructured":"Oeztuerk-Winder F, Ventura JJ (2012) The many faces of p38 mitogen-activated protein kinase in progenitor\/stem cell differentiation. Biochem J 445:1\u201310","journal-title":"Biochem J"},{"key":"10412_CR4","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3332\/ecancer.2017.715","volume":"11","author":"C Pulido","year":"2017","unstructured":"Pulido C et al (2017) Bone metastasis risk factors in breast cancer. eCancer 11:715","journal-title":"eCancer"},{"key":"10412_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s11914-019-00532-y","volume":"17","author":"ME Clements","year":"2019","unstructured":"Clements ME, Johnson RW (2019) Breast cancer dormancy in bone. Curr Osteoporos Rep 17:353\u2013361","journal-title":"Curr Osteoporos Rep"},{"key":"10412_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi S et al (2016) Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165:45\u201360","journal-title":"Cell"},{"key":"10412_CR7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2204758119","volume":"119","author":"R Roy","year":"2022","unstructured":"Roy R et al (2022) Escape from breast tumor dormancy: the convergence of obesity and menopause. Proc Natl Acad Sci U S A 119:e2204758119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10412_CR8","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrc1370","volume":"4","author":"K Pantel","year":"2004","unstructured":"Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4:448\u2013456","journal-title":"Nat Rev Cancer"},{"key":"10412_CR9","doi-asserted-by":"publisher","first-page":"5850","DOI":"10.1158\/1078-0432.CCR-10-2574","volume":"17","author":"MS Sosa","year":"2011","unstructured":"Sosa MS, Avivar-Valderas A, Bragado P, Wen HC, Aguirre-Ghiso JA (2011) ERK1\/2 and p38alpha\/beta signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res 17:5850\u20135857","journal-title":"Clin Cancer Res"},{"key":"10412_CR10","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1016\/j.ejca.2008.09.035","volume":"44","author":"CA Klein","year":"2008","unstructured":"Klein CA (2008) The direct molecular analysis of metastatic precursor cells in breast cancer: a chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer 44:2721\u20132725","journal-title":"Eur J Cancer"},{"key":"10412_CR11","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature20785","volume":"540","author":"H Hosseini","year":"2016","unstructured":"Hosseini H et al (2016) Early dissemination seeds metastasis in breast cancer. Nature 540:552\u2013558","journal-title":"Nature"},{"key":"10412_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.pharmthera.2015.02.002","volume":"150","author":"RW Johnson","year":"2015","unstructured":"Johnson RW, Schipani E, Giaccia AJ (2015) HIF targets in bone remodeling and metastatic disease. Pharmacol Ther 150:169\u2013177","journal-title":"Pharmacol Ther"},{"key":"10412_CR13","volume":"3","author":"V Mayhew","year":"2019","unstructured":"Mayhew V, Omokehinde T, Johnson RW (2019) Tumor dormancy in bone. Cancer Rep 3:e1156","journal-title":"Cancer Rep"},{"key":"10412_CR14","first-page":"1318","volume":"30","author":"DI Boxer","year":"1989","unstructured":"Boxer DI, Todd CEC, Coleman R, Fogelman I (1989) Bone secondaries in breast cancer: the solitary metastasis. J Nucl Med 30:1318\u20131320","journal-title":"J Nucl Med"},{"key":"10412_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1148\/112.2.361","volume":"112","author":"PH Shirazi","year":"1974","unstructured":"Shirazi PH, Rayudu GVS, Fordham EW (1974) 18F bone scanning: review of indications and results of 1,500 scans. Radiology 112:257\u2013512","journal-title":"Radiology"},{"key":"10412_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1148\/55.4.534","volume":"55","author":"HL Abrams","year":"1950","unstructured":"Abrams HL (1950) Skeletal metastases in carcinoma. Radiology 55:477\u2013640","journal-title":"Radiology"},{"key":"10412_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre-Ghiso JA (2014) Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer 14:611\u2013622","journal-title":"Nat Rev Cancer"},{"key":"10412_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/1568009615666150506092443","volume":"15","author":"L Quayle","year":"2015","unstructured":"Quayle L, Ottewell PD, Holen I (2015) Bone metastasis: molecular mechanisms implicated in tumour cell dormancy in breast and prostate cancer. Curr Cancer Drug Targets 15:469\u2013480","journal-title":"Curr Cancer Drug Targets"},{"key":"10412_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","volume":"66","author":"M-T Haider","year":"2014","unstructured":"Haider M-T, Holen I, Dear TN, Hunter K, Brown HK (2014) Modifying the osteoblastic niche with zoledronic acid in vivo\u2014potential implications for breast cancer bone metastasis. Bone 66:240\u2013250","journal-title":"Bone"},{"key":"10412_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee S, Behnam Azad B, Nimmagadda S (2014) The intricate role of CXCR4 in cancer. Adv Cancer Res 124:31\u201382","journal-title":"Adv Cancer Res"},{"key":"10412_CR21","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.bone.2005.10.003","volume":"38","author":"Y Jung","year":"2006","unstructured":"Jung Y et al (2006) Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 38:497\u2013508","journal-title":"Bone"},{"key":"10412_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/leu.2008.48","volume":"22","author":"Y Shiozawa","year":"2008","unstructured":"Shiozawa Y, Havens AM, Pienta KJ, Taichman RS (2008) The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22:941\u2013950","journal-title":"Leukemia"},{"key":"10412_CR23","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1038\/s41416-021-01329-6","volume":"124","author":"F Chen","year":"2021","unstructured":"Chen F, Han Y, Kang Y (2021) Bone marrow niches in the regulation of bone metastasis. Br J Cancer 124:1912\u20131920","journal-title":"Br J Cancer"},{"key":"10412_CR24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10555-006-9019-x","volume":"25","author":"J Wang","year":"2006","unstructured":"Wang J, Loberg R, Taichman RS (2006) The pivotal role of CXCL12 (SDF-1)\/CXCR4 axis in bone metastasis. Cancer Metastasis Rev 25:573\u2013587","journal-title":"Cancer Metastasis Rev"},{"key":"10412_CR25","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1182\/blood-2006-01-017459","volume":"108","author":"AL Moharita","year":"2006","unstructured":"Moharita AL et al (2006) SDF-1alpha regulation in breast cancer cells contacting bone marrow stroma is critical for normal hematopoiesis. Blood 108:3245\u20133252","journal-title":"Blood"},{"key":"10412_CR26","doi-asserted-by":"publisher","first-page":"340ra73","DOI":"10.1126\/scitranslmed.aad4059","volume":"8","author":"TT Price","year":"2016","unstructured":"Price TT et al (2016) Dormant breast cancer micrometastases reside in specific bone marrow niches that regulate their transit to and from bone. Sci Transl Med 8:340ra73","journal-title":"Sci Transl Med"},{"key":"10412_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395714","volume":"15","author":"J Souchak","year":"2024","unstructured":"Souchak J, Mohammed NBB, Lau LS, Dimitroff CJ (2024) The role of galectins in mediating the adhesion of circulating cells to vascular endothelium. Front Immunol 15:1395714","journal-title":"Front Immunol"},{"key":"10412_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12108-6","volume":"10","author":"R Romero-Moreno","year":"2019","unstructured":"Romero-Moreno R et al (2019) The CXCL5\/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat Commun 10:4404","journal-title":"Nat Commun"},{"key":"10412_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/(SICI)1097-0215(19970620)74:3<275::AID-IJC7>3.0.CO;2-W","volume":"74","author":"K Sundfeldt","year":"1997","unstructured":"Sundfeldt K et al (1997) E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int J Cancer 74:275\u2013280","journal-title":"Int J Cancer"},{"key":"10412_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10585-008-9167-1","volume":"25","author":"A Wells","year":"2008","unstructured":"Wells A, Yates C, Shepard CR (2008) E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 25:621\u2013628","journal-title":"Clin Exp Metastasis"},{"key":"10412_CR31","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1038\/s41467-022-32523-6","volume":"13","author":"P Aouad","year":"2022","unstructured":"Aouad P et al (2022) Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence. Nat Commun 13:4975","journal-title":"Nat Commun"},{"key":"10412_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrc3447","volume":"13","author":"B De Craene","year":"2013","unstructured":"De Craene B, Berx G (2013) Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13:97\u2013110","journal-title":"Nat Rev Cancer"},{"key":"10412_CR33","first-page":"4063","volume":"56","author":"G Mbalaviele","year":"1996","unstructured":"Mbalaviele G et al (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model1. Cancer Res 56:4063\u20134070","journal-title":"Cancer Res"},{"key":"10412_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tcb.2008.05.002","volume":"18","author":"RK Assoian","year":"2008","unstructured":"Assoian RK, Klein EA (2008) Growth control by intracellular tension and extracellular stiffness. Trends Cell Biol 18:347\u2013352","journal-title":"Trends Cell Biol"},{"key":"10412_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","volume":"10","author":"JS Desgrosellier","year":"2010","unstructured":"Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9\u201322","journal-title":"Nat Rev Cancer"},{"key":"10412_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201600430","volume":"17","author":"DN Meenakshi Sundaram","year":"2017","unstructured":"Meenakshi Sundaram DN, Kucharski C, Parmar MB, Kc RB, Uluda\u011f H (2017) Polymeric delivery of siRNA against integrin-\u03b21 (CD29) to reduce attachment and migration of breast cancer cells. Macromol Biosci 17:1600430","journal-title":"Macromol Biosci"},{"key":"10412_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0537-8","volume":"17","author":"Y Li","year":"2015","unstructured":"Li Y et al (2015) Genetic depletion and pharmacological targeting of \u03b1v integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Res 17:28","journal-title":"Breast Cancer Res"},{"key":"10412_CR38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1002\/path.4490","volume":"235","author":"RZ Carter","year":"2015","unstructured":"Carter RZ et al (2015) Tumour but not stromal expression of \u03b23 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer. J Pathol 235:760\u2013772","journal-title":"J Pathol"},{"key":"10412_CR39","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00432-021-03812-2","volume":"148","author":"S Arnold","year":"2022","unstructured":"Arnold S et al (2022) Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer. J Cancer Res Clin Oncol 148:1525\u20131542","journal-title":"J Cancer Res Clin Oncol"},{"key":"10412_CR40","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.1158\/0008-5472.CAN-06-4499","volume":"67","author":"Y Zhao","year":"2007","unstructured":"Zhao Y et al (2007) Tumor \u03b1v\u03b23 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res 67:5821\u20135830","journal-title":"Cancer Res"},{"key":"10412_CR41","doi-asserted-by":"publisher","first-page":"48684","DOI":"10.1074\/jbc.M308001200","volume":"278","author":"CK Inman","year":"2003","unstructured":"Inman CK, Shore P (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278:48684\u201348689","journal-title":"J Biol Chem"},{"key":"10412_CR42","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1186\/bcr2762","volume":"12","author":"DT Leong","year":"2010","unstructured":"Leong DT et al (2010) Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility. Breast Cancer Res BCR 12:R89","journal-title":"Breast Cancer Res BCR"},{"key":"10412_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.06.007","author":"X-Q Li","year":"2016","unstructured":"Li X-Q, Lu J-T, Tan C-C, Wang Q-S, Feng Y-M (2016) RUNX2 promotes breast cancer bone metastasis by increasing integrin \u03b15-mediated colonization. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2016.06.007","journal-title":"Cancer Lett"},{"key":"10412_CR44","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/s41388-020-01603-6","volume":"40","author":"F Pantano","year":"2021","unstructured":"Pantano F et al (2021) Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. Oncogene 40:1284\u20131299","journal-title":"Oncogene"},{"key":"10412_CR45","doi-asserted-by":"publisher","first-page":"eaaz4157","DOI":"10.1126\/sciadv.aaz4157","volume":"6","author":"LE Barney","year":"2020","unstructured":"Barney LE et al (2020) Tumor cell\u2013organized fibronectin maintenance of a dormant breast cancer population. Sci Adv 6:eaaz4157","journal-title":"Sci Adv"},{"key":"10412_CR46","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1016\/j.yexcr.2013.08.021","volume":"319","author":"E Kiwanuka","year":"2013","unstructured":"Kiwanuka E et al (2013) CCN2 promotes keratinocyte adhesion and migration via integrin \u03b15\u03b21. Exp Cell Res 319:2938\u20132946","journal-title":"Exp Cell Res"},{"key":"10412_CR47","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1242\/jcs.071985","volume":"124","author":"CT Mierke","year":"2011","unstructured":"Mierke CT, Frey B, Fellner M, Herrmann M, Fabry B (2011) Integrin \u03b15\u03b21 facilitates cancer cell invasion through enhanced contractile forces. J Cell Sci 124:369\u2013383","journal-title":"J Cell Sci"},{"key":"10412_CR48","doi-asserted-by":"publisher","first-page":"7133","DOI":"10.3390\/ijms25137133","volume":"25","author":"B Dai","year":"2024","unstructured":"Dai B, Clark AM, Wells A (2024) Mesenchymal stem cell-secreted exosomes and soluble signals regulate breast cancer metastatic dormancy: current progress and future outlook. Int J Mol Sci 25:7133","journal-title":"Int J Mol Sci"},{"key":"10412_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005231","volume":"7","author":"M Ono","year":"2014","unstructured":"Ono M et al (2014) Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 7:ra63","journal-title":"Sci Signal"},{"key":"10412_CR50","doi-asserted-by":"publisher","first-page":"E6447","DOI":"10.1073\/pnas.1612290113","volume":"113","author":"TJ Bartosh","year":"2016","unstructured":"Bartosh TJ, Ullah M, Zeitouni S, Beaver J, Prockop DJ (2016) Cancer cells enter dormancy after cannibalizing mesenchymal stem\/stromal cells (MSCs). Proc Natl Acad Sci U S A 113:E6447\u2013E6456","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10412_CR51","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12943-019-0994-2","volume":"18","author":"ME Fiori","year":"2019","unstructured":"Fiori ME et al (2019) Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol Cancer 18:70","journal-title":"Mol Cancer"},{"key":"10412_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-025-02328-2","volume":"11","author":"Y Liang","year":"2026","unstructured":"Liang Y, Chen W-M, Zhang Y, Li L (2026) Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Signal Transduct Target Ther 11:1","journal-title":"Signal Transduct Target Ther"},{"key":"10412_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11914-025-00949-8","volume":"24","author":"NV Giger","year":"2026","unstructured":"Giger NV, Wehrle E (2026) Advances in spatial transcriptomics in bone. Curr Osteoporos Rep 24:3","journal-title":"Curr Osteoporos Rep"},{"key":"10412_CR54","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1158\/0008-5472.CAN-13-0305","volume":"73","author":"A Sawant","year":"2013","unstructured":"Sawant A, Ponnazhagan S (2013) Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis. Cancer Res 73:4606\u20134610","journal-title":"Cancer Res"},{"key":"10412_CR55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM et al (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15:807\u2013817","journal-title":"Nat Cell Biol"},{"key":"10412_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215482","volume":"14","author":"T Kawano","year":"2019","unstructured":"Kawano T et al (2019) Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice. PLoS ONE 14:e0215482","journal-title":"PLoS ONE"},{"key":"10412_CR57","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1172\/JCI57229","volume":"121","author":"LG Schuettpelz","year":"2011","unstructured":"Schuettpelz LG, Link DC (2011) Niche competition and cancer metastasis to bone. J Clin Invest 121:1253\u20131255","journal-title":"J Clin Invest"},{"key":"10412_CR58","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1158\/0008-5472.CAN-16-1092","volume":"76","author":"SA Bliss","year":"2016","unstructured":"Bliss SA et al (2016) Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res 76:5832\u20135844","journal-title":"Cancer Res"},{"key":"10412_CR59","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/0008-5472.CAN-20-2434","volume":"81","author":"OA Sandiford","year":"2021","unstructured":"Sandiford OA et al (2021) Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. Cancer Res 81:1567\u20131582","journal-title":"Cancer Res"},{"key":"10412_CR60","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1158\/0008-5472.CAN-10-2372","volume":"71","author":"PK Lim","year":"2011","unstructured":"Lim PK et al (2011) Gap junction-mediated import of MicroRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res 71:1550\u20131560","journal-title":"Cancer Res"},{"key":"10412_CR61","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1158\/0008-5472.CAN-08-3820","volume":"69","author":"AP Adam","year":"2009","unstructured":"Adam AP et al (2009) Computational identification of a p38SAPK-regulated transcription factor network required for tumor cell quiescence. Cancer Res 69:5664\u20135672","journal-title":"Cancer Res"},{"key":"10412_CR62","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s43018-021-00179-8","volume":"2","author":"AR Nobre","year":"2021","unstructured":"Nobre AR et al (2021) Bone marrow NG2(+)\/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGFbeta2. Nat Cancer 2:327\u2013339","journal-title":"Nat Cancer"},{"key":"10412_CR63","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41556-017-0021-z","volume":"20","author":"S Gawrzak","year":"2018","unstructured":"Gawrzak S et al (2018) MSK1 regulates luminal cell differentiation and metastatic dormancy in ER(+) breast cancer. Nat Cell Biol 20:211\u2013221","journal-title":"Nat Cell Biol"},{"key":"10412_CR64","first-page":"409","volume":"62","author":"M J\u00f6nsson","year":"2002","unstructured":"J\u00f6nsson M, Dejmek J, Bendahl P-O, Andersson T (2002) Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast Carcinomas1. Cancer Res 62:409\u2013416","journal-title":"Cancer Res"},{"key":"10412_CR65","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3121\/cmr.2008.825","volume":"7","author":"AA Onitilo","year":"2009","unstructured":"Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER\/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4\u201313","journal-title":"Clin Med Res"},{"issue":"Suppl 1","key":"10412_CR66","first-page":"S65","volume":"38","author":"A Carnero","year":"2016","unstructured":"Carnero A, Lleonart M (2016) The hypoxic microenvironment: a determinant of cancer stem cell evolution. BioEssays 38(Suppl 1):S65-74","journal-title":"BioEssays"},{"key":"10412_CR67","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ncb3465","volume":"19","author":"G Fluegen","year":"2017","unstructured":"Fluegen G et al (2017) Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol 19:120\u2013132","journal-title":"Nat Cell Biol"},{"key":"10412_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1401113","volume":"14","author":"L Sui","year":"2024","unstructured":"Sui L, Wang J, Jiang WG, Song X, Ye L (2024) Molecular mechanism of bone metastasis in breast cancer. Front Oncol 14:1401113","journal-title":"Front Oncol"},{"key":"10412_CR69","doi-asserted-by":"publisher","first-page":"6999","DOI":"10.3390\/ijms24086999","volume":"24","author":"C Li","year":"2023","unstructured":"Li C, Zhao R, Yang H, Ren L (2023) Construction of bone hypoxic microenvironment based on bone-on-a-chip platforms. Int J Mol Sci 24:6999","journal-title":"Int J Mol Sci"},{"key":"10412_CR70","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F et al (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623\u20131649","journal-title":"Ann Oncol"},{"key":"10412_CR71","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.3390\/cancers14215388","volume":"14","author":"M Abdelmalak","year":"2022","unstructured":"Abdelmalak M et al (2022) The renaissance of CDK inhibitors in breast cancer therapy: an update on clinical trials and therapy resistance. Cancers 14:5388","journal-title":"Cancers"},{"key":"10412_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00931-8","volume":"9","author":"HE Marei","year":"2025","unstructured":"Marei HE et al (2025) Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues. Npj Precis Oncol 9:204","journal-title":"Npj Precis Oncol"},{"key":"10412_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101103","volume":"76","author":"A Glaviano","year":"2024","unstructured":"Glaviano A et al (2024) Mechanisms of sensitivity and resistance to CDK4\/CDK6 inhibitors in hormone receptor-positive breast cancer treatment. Drug Resist Updat 76:101103","journal-title":"Drug Resist Updat"},{"key":"10412_CR74","first-page":"862","volume":"23","author":"A Hassanzadeh","year":"2024","unstructured":"Hassanzadeh A et al (2024) Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside. EXCLI J 23:862\u2013882","journal-title":"EXCLI J"},{"key":"10412_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218097","volume":"635","author":"Y Wang","year":"2025","unstructured":"Wang Y, Liu L, Zhang X, Liang T, Bai X (2025) Cancer dormancy and metabolism: from molecular insights to translational opportunities. Cancer Lett 635:218097","journal-title":"Cancer Lett"},{"key":"10412_CR76","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/362938","volume":"2011","author":"M Chaterjee","year":"2011","unstructured":"Chaterjee M, van Golen KL (2011) Breast cancer stem cells survive periods of farnesyl-transferase inhibitor-induced dormancy by undergoing autophagy. Bone Marrow Res 2011:362938","journal-title":"Bone Marrow Res"},{"key":"10412_CR77","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1091\/mbc.e08-12-1248","volume":"20","author":"N Hosokawa","year":"2009","unstructured":"Hosokawa N et al (2009) Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 20:1981\u20131991","journal-title":"Mol Biol Cell"},{"key":"10412_CR78","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04070-6","volume":"9","author":"L Vera-Ramirez","year":"2018","unstructured":"Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE (2018) Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun 9:1944","journal-title":"Nat Commun"},{"key":"10412_CR79","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","volume":"110","author":"DH Kim","year":"2002","unstructured":"Kim DH et al (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110:163\u2013175","journal-title":"Cell"},{"key":"10412_CR80","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science 331:1565\u20131570","journal-title":"Science"},{"key":"10412_CR81","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cell.2017.11.037","volume":"172","author":"AD Barrow","year":"2018","unstructured":"Barrow AD et al (2018) Natural killer cells control tumor growth by sensing a growth factor. Cell 172:534-548.e19","journal-title":"Cell"},{"key":"10412_CR82","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-24-0030","volume":"84","author":"GG Bushnell","year":"2024","unstructured":"Bushnell GG et al (2024) Natural killer cell regulation of breast cancer stem cells mediates metastatic dormancy. Cancer Res 84:3337\u20133353","journal-title":"Cancer Res"},{"key":"10412_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ph17121591","volume":"17","author":"FN Hamza","year":"2024","unstructured":"Hamza FN, Mohammad KS (2024) Immunotherapy in the battle against bone metastases: mechanisms and emerging treatments. Pharmaceuticals 17:1591","journal-title":"Pharmaceuticals"},{"key":"10412_CR84","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1007\/s13277-014-1859-3","volume":"35","author":"MT Isla Larrain","year":"2014","unstructured":"Isla Larrain MT et al (2014) IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis. Tumor Biol 35:6511\u20136519","journal-title":"Tumor Biol"},{"key":"10412_CR85","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10694","volume":"7","author":"ME Clements","year":"2023","unstructured":"Clements ME, Holtslander L, Johnson JR, Johnson RW (2023) Select HDAC inhibitors enhance osteolysis and bone metastasis outgrowth but can be mitigated with bisphosphonate therapy. JBMR Plus 7:e10694","journal-title":"JBMR Plus"},{"key":"10412_CR86","doi-asserted-by":"publisher","first-page":"5314","DOI":"10.1038\/s41388-021-01931-1","volume":"40","author":"ME Clements","year":"2021","unstructured":"Clements ME et al (2021) HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. Oncogene 40:5314\u20135326","journal-title":"Oncogene"},{"key":"10412_CR87","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ncb3408","volume":"18","author":"RW Johnson","year":"2016","unstructured":"Johnson RW et al (2016) Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol 18:1078\u20131089","journal-title":"Nat Cell Biol"},{"key":"10412_CR88","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11914-021-00670-2","volume":"19","author":"CM Edwards","year":"2021","unstructured":"Edwards CM, Johnson RW (2021) Targeting histone modifications in bone and lung metastatic cancers. Curr Osteoporos Rep 19:230\u2013246","journal-title":"Curr Osteoporos Rep"},{"key":"10412_CR89","doi-asserted-by":"publisher","first-page":"e13107","DOI":"10.1200\/JCO.2023.41.16_suppl.e13107","volume":"41","author":"C Humphrey","year":"2023","unstructured":"Humphrey C et al (2023) A pilot study of the combination of entinostat with capecitabine in high-risk breast cancer after neoadjuvant therapy. J Clin Oncol 41:e13107\u2013e13107","journal-title":"J Clin Oncol"},{"key":"10412_CR90","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1200\/JCO.21.00944","volume":"39","author":"RM Connolly","year":"2021","unstructured":"Connolly RM et al (2021) E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer: a trial of the ECOG-ACRIN cancer research group. J Clin Oncol 39:3171\u20133181","journal-title":"J Clin Oncol"},{"key":"10412_CR91","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1200\/JCO.2020.38.15_suppl.1014","volume":"38","author":"J O\u2019Shaughnessy","year":"2020","unstructured":"O\u2019Shaughnessy J et al (2020) Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). J Clin Oncol 38:1014\u20131014","journal-title":"J Clin Oncol"},{"key":"10412_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100524","volume":"44","author":"MB Searcy","year":"2024","unstructured":"Searcy MB, Johnson RW (2024) Epigenetic control of the vicious cycle. J Bone Oncol 44:100524","journal-title":"J Bone Oncol"},{"key":"10412_CR93","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1038\/s41467-024-46602-3","volume":"15","author":"Y Zhao","year":"2024","unstructured":"Zhao Y et al (2024) Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis. Nat Commun 15:2384","journal-title":"Nat Commun"},{"key":"10412_CR94","doi-asserted-by":"publisher","first-page":"903","DOI":"10.21037\/atm.2020.02.177","volume":"8","author":"NJ Robinson","year":"2020","unstructured":"Robinson NJ, Parker KA, Schiemann WP (2020) Epigenetic plasticity in metastatic dormancy: mechanisms and therapeutic implications. Ann Transl Med 8:903\u2013903","journal-title":"Ann Transl Med"},{"key":"10412_CR95","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1600-0463.2008.01033.x","volume":"116","author":"H Wikman","year":"2008","unstructured":"Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour dormancy. APMIS 116:754\u2013770","journal-title":"APMIS"},{"key":"10412_CR96","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.ccr.2011.11.002","volume":"20","author":"X Lu","year":"2011","unstructured":"Lu X et al (2011) VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20:701\u2013714","journal-title":"Cancer Cell"},{"key":"10412_CR97","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/ijc.29439","volume":"137","author":"PD Ottewell","year":"2015","unstructured":"Ottewell PD et al (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer 137:968\u2013977","journal-title":"Int J Cancer"},{"key":"10412_CR98","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/annonc\/mdm442","volume":"19","author":"M Aapro","year":"2008","unstructured":"Aapro M et al (2008) Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19:420\u2013432","journal-title":"Ann Oncol"},{"key":"10412_CR99","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000322043","volume":"5","author":"IJ Diel","year":"2010","unstructured":"Diel IJ (2010) Bisphosphonates in breast cancer patients with bone metastases. Breast Care 5:306\u2013311","journal-title":"Breast Care"},{"key":"10412_CR100","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","volume":"20","author":"PD Ottewell","year":"2014","unstructured":"Ottewell PD et al (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20:2922\u20132932","journal-title":"Clin Cancer Res"},{"key":"10412_CR101","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41416-020-01043-9","volume":"123","author":"Y-Y Li","year":"2020","unstructured":"Li Y-Y et al (2020) Bisphosphonates and risk of cancers: a systematic review and meta-analysis. Br J Cancer 123:1570\u20131581","journal-title":"Br J Cancer"},{"key":"10412_CR102","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet 386:433\u2013443","journal-title":"The Lancet"},{"key":"10412_CR103","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT et al (2010) Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, Double-Blind Study. J Clin Oncol 28:5132\u20135139","journal-title":"J Clin Oncol"},{"key":"10412_CR104","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS et al (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer 98:1735\u20131744","journal-title":"Cancer"},{"key":"10412_CR105","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D et al (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663\u2013670","journal-title":"Lancet Oncol"},{"key":"10412_CR106","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","volume":"3","author":"GN Hortobagyi","year":"2017","unstructured":"Hortobagyi GN et al (2017) Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 3:906\u2013912","journal-title":"JAMA Oncol"},{"key":"10412_CR107","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","volume":"317","author":"AL Himelstein","year":"2017","unstructured":"Himelstein AL et al (2017) Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 317:48\u201358","journal-title":"JAMA"},{"key":"10412_CR108","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol 15:997\u20131006","journal-title":"Lancet Oncol"},{"key":"10412_CR109","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/bonekey.2014.95","volume":"3","author":"A-H Capietto","year":"2014","unstructured":"Capietto A-H, Faccio R (2014) Immune regulation of bone metastasis. BoneKEy Rep 3:600","journal-title":"BoneKEy Rep"},{"key":"10412_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"Q Zhang","year":"2012","unstructured":"Zhang Q et al (2012) Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7:e50946","journal-title":"PLoS ONE"},{"key":"10412_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10125","volume":"3","author":"NM Byrne","year":"2019","unstructured":"Byrne NM, Summers MA, McDonald MM (2019) Tumor cell dormancy and reactivation in bone: skeletal biology and therapeutic opportunities. JBMR Plus 3:e10125","journal-title":"JBMR Plus"},{"key":"10412_CR112","doi-asserted-by":"publisher","first-page":"e13166","DOI":"10.1200\/JCO.2025.43.16_suppl.e13166","volume":"43","author":"K Jiang","year":"2025","unstructured":"Jiang K, Xu F (2025) Denosumab monotherapy versus bisphosphonate switching in breast cancer bone metastases: a real-world cohort study on skeletal events and safety. J Clin Oncol 43:e13166\u2013e13166","journal-title":"J Clin Oncol"},{"key":"10412_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61020360","volume":"61","author":"\u0130 \u00d6ner","year":"2025","unstructured":"\u00d6ner \u0130 et al (2025) A comparison of the efficacy and safety of Denosumab and Zoledronic Acid in patients with bone metastatic breast cancer receiving CDK4\/6 inhibitor therapy. Medicina (Mex) 61:360","journal-title":"Medicina (Mex)"},{"key":"10412_CR114","unstructured":"Amgen. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE). https:\/\/clinicaltrials.gov\/study\/NCT01077154 (2021)"},{"key":"10412_CR115","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S8756-3282(02)00685-3","volume":"30","author":"TA Guise","year":"2002","unstructured":"Guise TA et al (2002) Parathyroid hormone-related protein (PTHrP)-(1\u2013139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 30:670\u2013676","journal-title":"Bone"},{"key":"10412_CR116","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1172\/JCI118947","volume":"98","author":"TA Guise","year":"1996","unstructured":"Guise TA et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98:1544\u20131549","journal-title":"J Clin Invest"},{"key":"10412_CR117","doi-asserted-by":"publisher","first-page":"13909","DOI":"10.1073\/pnas.0506517102","volume":"102","author":"Y Kang","year":"2005","unstructured":"Kang Y et al (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U A 102:13909\u201313914","journal-title":"Proc Natl Acad Sci U A"},{"key":"10412_CR118","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cell.2012.06.035","volume":"150","author":"H Gao","year":"2012","unstructured":"Gao H et al (2012) The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 150:764\u2013779","journal-title":"Cell"},{"key":"10412_CR119","doi-asserted-by":"publisher","first-page":"71362","DOI":"10.18632\/oncotarget.12109","volume":"7","author":"K Weidenfeld","year":"2016","unstructured":"Weidenfeld K et al (2016) Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth. Oncotarget 7:71362\u201371377","journal-title":"Oncotarget"},{"key":"10412_CR120","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cpt.2025.07.003","volume":"4","author":"AH Shaikat","year":"2026","unstructured":"Shaikat AH et al (2026) Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathog Ther 4:174\u2013191","journal-title":"Cancer Pathog Ther"},{"key":"10412_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1227884","volume":"13","author":"GM Abd","year":"2023","unstructured":"Abd GM, Laird MC, Ku JC, Li Y (2023) Hypoxia-induced cancer cell reprogramming: a review on how cancer stem cells arise. Front Oncol 13:1227884","journal-title":"Front Oncol"},{"key":"10412_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20174305","volume":"20","author":"E Butturini","year":"2019","unstructured":"Butturini E, Carcereri de Prati A, Boriero D, Mariotto S (2019) Tumor dormancy and interplay with hypoxic tumor microenvironment. Int J Mol Sci 20:4305","journal-title":"Int J Mol Sci"},{"key":"10412_CR123","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.25176","volume":"127","author":"EK Rofstad","year":"2010","unstructured":"Rofstad EK, Gaustad J-V, Egeland TAM, Mathiesen B, Galappathi K (2010) Tumors exposed to acute cyclic hypoxic stress show enhanced angiogenesis, perfusion and metastatic dissemination. Int J Cancer 127:1535\u20131546","journal-title":"Int J Cancer"},{"key":"10412_CR124","doi-asserted-by":"publisher","first-page":"10961","DOI":"10.1007\/s11033-022-07802-6","volume":"49","author":"Q Liu","year":"2022","unstructured":"Liu Q, Palmgren VAC, Danen EH, Le D\u00e9v\u00e9dec SE (2022) Acute vs. chronic vs. intermittent hypoxia in breast cancer: a review on its application in in vitro research. Mol Biol Rep 49:10961\u201310973","journal-title":"Mol Biol Rep"},{"key":"10412_CR125","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1242\/dev.00578","volume":"130","author":"EA Kritikou","year":"2003","unstructured":"Kritikou EA et al (2003) A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 130:3459\u20133468","journal-title":"Development"},{"key":"10412_CR126","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/0008-5472.CAN-09-2715","volume":"70","author":"IM Pires","year":"2010","unstructured":"Pires IM et al (2010) Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 70:925\u2013935","journal-title":"Cancer Res"},{"key":"10412_CR127","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2011.02.049","volume":"80","author":"C Bayer","year":"2011","unstructured":"Bayer C, Shi K, Astner ST, Maftei C-A, Vaupel P (2011) Acute versus chronic hypoxia: why a simplified classification is simply not enough. Int J Radiat Oncol Biol Phys 80:965\u2013968","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10412_CR128","doi-asserted-by":"publisher","first-page":"9482","DOI":"10.1073\/pnas.1633689100","volume":"100","author":"M Rolli","year":"2003","unstructured":"Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B (2003) Activated integrin \u03b1v\u03b23 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci U S A 100:9482\u20139487","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10412_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029615","volume":"7","author":"M Shah","year":"2012","unstructured":"Shah M et al (2012) An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. PLoS ONE 7:e29615","journal-title":"PLoS ONE"},{"key":"10412_CR130","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bjc.2015.221","volume":"113","author":"AM Grawenda","year":"2015","unstructured":"Grawenda AM, O\u2019Neill E (2015) Clinical utility of RASSF1A methylation in human malignancies. Br J Cancer 113:372\u2013381","journal-title":"Br J Cancer"},{"key":"10412_CR131","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1158\/1078-0432.CCR-03-0118","volume":"10","author":"J Mehrotra","year":"2004","unstructured":"Mehrotra J et al (2004) Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung. Clin Cancer Res 10:3104\u20133109","journal-title":"Clin Cancer Res"},{"key":"10412_CR132","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.1016\/j.cell.2021.10.024","volume":"184","author":"K Zhang","year":"2021","unstructured":"Zhang K et al (2021) A single-cell atlas of chromatin accessibility in the human genome. Cell 184:5985-6001.e19","journal-title":"Cell"},{"key":"10412_CR133","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1745-7270.2008.00442.x","volume":"40","author":"X Gao","year":"2008","unstructured":"Gao X, Xu Z (2008) Mechanisms of action of angiogenin. Acta Biochim Biophys Sin 40:619\u2013624","journal-title":"Acta Biochim Biophys Sin"},{"key":"10412_CR134","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nrc3536","volume":"13","author":"MH Barcellos-Hoff","year":"2013","unstructured":"Barcellos-Hoff MH, Lyden D, Wang TC (2013) The evolution of the cancer niche during multistage carcinogenesis. Nat Rev Cancer 13:511\u2013518","journal-title":"Nat Rev Cancer"},{"key":"10412_CR135","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/djj068","volume":"98","author":"GN Naumov","year":"2006","unstructured":"Naumov GN et al (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316\u2013325","journal-title":"J Natl Cancer Inst"},{"key":"10412_CR136","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1158\/0008-5472.CAN-10-3684","volume":"71","author":"J Laurent","year":"2011","unstructured":"Laurent J et al (2011) Proangiogenic factor PlGF programs CD11b+ myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res 71:3781\u20133791","journal-title":"Cancer Res"},{"key":"10412_CR137","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549\u2013555","journal-title":"Trends Immunol"},{"key":"10412_CR138","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni.1937","volume":"11","author":"SK Biswas","year":"2010","unstructured":"Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889\u2013896","journal-title":"Nat Immunol"},{"key":"10412_CR139","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI3523","volume":"103","author":"JJ Yin","year":"1999","unstructured":"Yin JJ et al (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 103:197\u2013206","journal-title":"J Clin Invest"},{"key":"10412_CR140","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1038\/s41467-019-12807-0","volume":"10","author":"R Eyre","year":"2019","unstructured":"Eyre R et al (2019) Microenvironmental IL1beta promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat Commun 10:5016","journal-title":"Nat Commun"},{"key":"10412_CR141","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315422","volume":"23","author":"D Bellavia","year":"2022","unstructured":"Bellavia D et al (2022) The binomial \u2018inflammation-epigenetics\u2019 in breast cancer progression and bone metastasis: IL-1\u03b2 actions are influenced by TET inhibitor in MCF-7 cell line. Int J Mol Sci 23:15422","journal-title":"Int J Mol Sci"},{"key":"10412_CR142","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10585-015-9710-9","volume":"32","author":"DM Sosnoski","year":"2015","unstructured":"Sosnoski DM, Norgard RJ, Grove CD, Foster SJ, Mastro AM (2015) Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment. Clin Exp Metastasis 32:335\u2013344","journal-title":"Clin Exp Metastasis"},{"key":"10412_CR143","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-021-00305-w","volume":"7","author":"C Tulotta","year":"2021","unstructured":"Tulotta C et al (2021) IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer 7:95","journal-title":"NPJ Breast Cancer"},{"key":"10412_CR144","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-18-2202","volume":"25","author":"C Tulotta","year":"2019","unstructured":"Tulotta C et al (2019) Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res 25:2769\u20132782","journal-title":"Clin Cancer Res"},{"key":"10412_CR145","doi-asserted-by":"publisher","first-page":"R421","DOI":"10.1530\/ERC-17-0309","volume":"25","author":"C Tulotta","year":"2018","unstructured":"Tulotta C, Ottewell P (2018) The role of IL-1B in breast cancer bone metastasis. Endocr Relat Cancer 25:R421\u2013R434","journal-title":"Endocr Relat Cancer"},{"key":"10412_CR146","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1530\/ERC-13-0158","volume":"21","author":"F Nutter","year":"2014","unstructured":"Nutter F et al (2014) Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer 21:327\u2013341","journal-title":"Endocr Relat Cancer"},{"key":"10412_CR147","doi-asserted-by":"publisher","first-page":"75571","DOI":"10.18632\/oncotarget.12289","volume":"7","author":"I Holen","year":"2016","unstructured":"Holen I et al (2016) IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget 7:75571\u201375584","journal-title":"Oncotarget"},{"key":"10412_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00241","volume":"9","author":"RW Johnson","year":"2018","unstructured":"Johnson RW et al (2018) Parathyroid Hormone-Related Protein negatively regulates tumor cell dormancy genes in a PTHR1\/Cyclic AMP-independent manner. Front Endocrinol 9:241","journal-title":"Front Endocrinol"},{"key":"10412_CR149","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1016\/j.febslet.2008.06.033","volume":"582","author":"JL Lin","year":"2008","unstructured":"Lin JL, Wang MJ, Lee D, Liang CC, Lin S (2008) Hypoxia-inducible factor-1alpha regulates matrix metalloproteinase-1 activity in human bone marrow-derived mesenchymal stem cells. FEBS Lett 582:2615\u20132619","journal-title":"FEBS Lett"},{"key":"10412_CR150","first-page":"3059","volume":"51","author":"GJ Powell","year":"1991","unstructured":"Powell GJ et al (1991) Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites1. Cancer Res 51:3059\u20133061","journal-title":"Cancer Res"},{"key":"10412_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15102670","volume":"15","author":"JF Kane","year":"2023","unstructured":"Kane JF, Johnson RW (2023) Re-evaluating the role of PTHrP in breast cancer. Cancers 15:2670","journal-title":"Cancers"},{"key":"10412_CR152","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1111\/bph.14709","volume":"178","author":"TJ Martin","year":"2021","unstructured":"Martin TJ, Johnson RW (2021) Multiple actions of PTHrP in breast cancer bone metastasis. Br J Pharmacol 178:1923\u20131935","journal-title":"Br J Pharmacol"},{"key":"10412_CR153","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ccr.2010.12.022","volume":"19","author":"N Sethi","year":"2011","unstructured":"Sethi N, Dai X, Winter CG, Kang Y (2011) Tumor-derived Jagged1 promotes osteolytic bone metastasis of breast cancer by engaging Notch signaling in bone cells. Cancer Cell 19:192\u2013205","journal-title":"Cancer Cell"},{"key":"10412_CR154","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-3-030-20301-6_7","volume-title":"Breast cancer metastasis and drug resistance: challenges and progress","author":"RK Tahara","year":"2019","unstructured":"Tahara RK, Brewer TM, Theriault RL, Ueno NT (2019) Bone metastasis of breast cancer. In: Ahmad A (ed) Breast cancer metastasis and drug resistance: challenges and progress. Springer, Cham, pp 105\u2013129"},{"key":"10412_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30105-0","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L et al (2022) EZH2 engages TGF\u03b2 signaling to promote breast cancer bone metastasis via integrin \u03b21-FAK activation. Nat Commun 13:2543","journal-title":"Nat Commun"},{"key":"10412_CR156","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01394-8","volume":"20","author":"Y Xu","year":"2021","unstructured":"Xu Y et al (2021) Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-\u03baB\/bone remodeling factors signaling. Mol Cancer 20:98","journal-title":"Mol Cancer"},{"key":"10412_CR157","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adr3997","volume":"10","author":"S Bakhshandeh","year":"2024","unstructured":"Bakhshandeh S et al (2024) Dormancy-inducing 3D engineered matrix uncovers mechanosensitive and drug-protective FHL2-p21 signaling axis. Sci Adv 10:eadr3997","journal-title":"Sci Adv"},{"key":"10412_CR158","doi-asserted-by":"publisher","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-09-2356","volume":"70","author":"D Barkan","year":"2010","unstructured":"Barkan D et al (2010) Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 70:5706\u20135716","journal-title":"Cancer Res"},{"key":"10412_CR159","doi-asserted-by":"publisher","first-page":"6241","DOI":"10.1158\/0008-5472.CAN-07-6849","volume":"68","author":"D Barkan","year":"2008","unstructured":"Barkan D et al (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68:6241\u20136250","journal-title":"Cancer Res"},{"key":"10412_CR160","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.1158\/0008-5472.CAN-13-0991","volume":"73","author":"R Marlow","year":"2013","unstructured":"Marlow R et al (2013) A novel model of dormancy for bone metastatic breast cancer cells. Cancer Res 73:6886\u20136899","journal-title":"Cancer Res"},{"key":"10412_CR161","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade3186","volume":"9","author":"L Pradhan","year":"2023","unstructured":"Pradhan L et al (2023) Dynamic bioinspired coculture model for probing ER+ breast cancer dormancy in the bone marrow niche. Sci Adv 9:eade3186","journal-title":"Sci Adv"},{"key":"10412_CR162","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.stem.2020.03.007","volume":"26","author":"K Ganesh","year":"2020","unstructured":"Ganesh K (2020) Plasticity in motion: Shape-shifting Lgr5\u2212 cells initiate colorectal cancer metastasis. Cell Stem Cell 26:469\u2013471","journal-title":"Cell Stem Cell"},{"key":"10412_CR163","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1126\/science.aao2774","volume":"359","author":"G Vlachogiannis","year":"2018","unstructured":"Vlachogiannis G et al (2018) Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359:920\u2013926","journal-title":"Science"},{"key":"10412_CR164","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1083\/jcb.147.1.89","volume":"147","author":"JA Aguirre Ghiso","year":"1999","unstructured":"Aguirre Ghiso JA, Kovalski K, Ossowski L (1999) Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol 147:89\u2013104","journal-title":"J Cell Biol"},{"key":"10412_CR165","first-page":"1684","volume":"63","author":"JA Aguirre-Ghiso","year":"2003","unstructured":"Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63:1684\u20131695","journal-title":"Cancer Res"},{"key":"10412_CR166","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1091\/mbc.12.4.863","volume":"12","author":"JA Aguirre-Ghiso","year":"2001","unstructured":"Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L (2001) Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12:863\u2013879","journal-title":"Mol Biol Cell"},{"key":"10412_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120624","volume":"269","author":"W Han","year":"2021","unstructured":"Han W et al (2021) In vitro bone metastasis dwelling in a 3D bioengineered niche. Biomaterials 269:120624","journal-title":"Biomaterials"},{"key":"10412_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/s13036-018-0137-0","volume":"13","author":"SS Rao","year":"2019","unstructured":"Rao SS, Kondapaneni RV, Narkhede AA (2019) Bioengineered models to study tumor dormancy. J Biol Eng 13:3","journal-title":"J Biol Eng"},{"key":"10412_CR169","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122163","volume":"299","author":"EC Gonz\u00e1lez D\u00edaz","year":"2023","unstructured":"Gonz\u00e1lez D\u00edaz EC, Tai M, Monette CEF, Wu JY, Yang F (2023) Spatially patterned 3D model mimics key features of cancer metastasis to bone. Biomaterials 299:122163","journal-title":"Biomaterials"},{"key":"10412_CR170","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1172\/JCI70259","volume":"124","author":"LHE Touny","year":"2014","unstructured":"Touny LHE et al (2014) Combined SFK\/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest 124:156\u2013168","journal-title":"J Clin Invest"},{"key":"10412_CR171","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201702787","volume":"14","author":"S Hao","year":"2018","unstructured":"Hao S et al (2018) A spontaneous 3D bone-on-a-chip for bone metastasis study of breast cancer cells. Small 14:1702787","journal-title":"Small"},{"key":"10412_CR172","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.biomaterials.2013.11.050","volume":"35","author":"S Bersini","year":"2014","unstructured":"Bersini S et al (2014) A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials 35:2454\u20132461","journal-title":"Biomaterials"},{"key":"10412_CR173","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1073\/pnas.1417115112","volume":"112","author":"JS Jeon","year":"2015","unstructured":"Jeon JS et al (2015) Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci 112:214\u2013219","journal-title":"Proc Natl Acad Sci"},{"key":"10412_CR174","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1074\/mcp.RA117.000370","volume":"17","author":"AM Clark","year":"2018","unstructured":"Clark AM et al (2018) A model of dormant-emergent metastatic breast cancer progression enabling exploration of biomarker signatures*. Mol Cell Proteomics 17:619\u2013630","journal-title":"Mol Cell Proteomics"},{"key":"10412_CR175","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s42242-020-00074-8","volume":"3","author":"F Sharifi","year":"2020","unstructured":"Sharifi F et al (2020) A hepatocellular carcinoma\u2013bone metastasis-on-a-chip model for studying thymoquinone-loaded anticancer nanoparticles. Bio-Des Manuf 3:189\u2013202","journal-title":"Bio-Des Manuf"},{"key":"10412_CR176","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.addr.2014.12.007","volume":"94","author":"CS Khoon","year":"2015","unstructured":"Khoon CS (2015) Experimental models of bone metastasis: Opportunities for the study of cancer dormancy. Adv Drug Deliv Rev 94:141\u2013150","journal-title":"Adv Drug Deliv Rev"},{"key":"10412_CR177","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nmeth.2938","volume":"11","author":"Y Torisawa","year":"2014","unstructured":"Torisawa Y et al (2014) Bone marrow\u2013on\u2013a\u2013chip replicates hematopoietic niche physiology in vitro. Nat Methods 11:663\u2013669","journal-title":"Nat Methods"},{"key":"10412_CR178","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/bonekey.2016.49","volume":"5","author":"S Marino","year":"2016","unstructured":"Marino S, Staines KA, Brown G, Howard-Jones RA, Adamczyk M (2016) Models of ex vivo explant cultures: applications in bone research. BoneKEy Rep 5:818","journal-title":"BoneKEy Rep"},{"key":"10412_CR179","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.3390\/cancers12082315","volume":"12","author":"R Laranga","year":"2020","unstructured":"Laranga R et al (2020) Trends in bone metastasis modeling. Cancers 12:2315","journal-title":"Cancers"},{"key":"10412_CR180","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10345","volume":"4","author":"T Bellido","year":"2020","unstructured":"Bellido T, Delgado Calle J (2020) Ex vivo organ cultures as models to study bone biology. JBMR Plus 4:e10345","journal-title":"JBMR Plus"},{"key":"10412_CR181","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11914-020-00649-5","volume":"19","author":"EEA Cramer","year":"2021","unstructured":"Cramer EEA, Ito K, Hofmann S (2021) Ex vivo bone models and their potential in preclinical evaluation. Curr Osteoporos Rep 19:75\u201387","journal-title":"Curr Osteoporos Rep"},{"key":"10412_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-32653-2","volume":"8","author":"ME Sowder","year":"2018","unstructured":"Sowder ME, Johnson RW (2018) Enrichment and detection of bone disseminated tumor cells in models of low tumor burden. Sci Rep 8:14299","journal-title":"Sci Rep"},{"key":"10412_CR183","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/s43018-023-00525-y","volume":"4","author":"FK Turrell","year":"2023","unstructured":"Turrell FK et al (2023) Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse. Nat Cancer 4:468\u2013484","journal-title":"Nat Cancer"},{"key":"10412_CR184","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02596-y","volume":"4","author":"D Ma","year":"2021","unstructured":"Ma D et al (2021) Patient-derived xenograft culture-transplant system for investigation of human breast cancer metastasis. Commun Biol 4:1268","journal-title":"Commun Biol"},{"key":"10412_CR185","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-022-00527-5","volume":"23","author":"D Entenberg","year":"2023","unstructured":"Entenberg D, Oktay MH, Condeelis JS (2023) Intravital imaging to study cancer progression and metastasis. Nat Rev Cancer 23:25\u201342","journal-title":"Nat Rev Cancer"},{"key":"10412_CR186","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/nprot.2011.376","volume":"6","author":"D Entenberg","year":"2011","unstructured":"Entenberg D et al (2011) Setup and use of a two-laser multiphoton microscope for multichannel intravital fluorescence imaging. Nat Protoc 6:1500\u20131520","journal-title":"Nat Protoc"},{"key":"10412_CR187","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/nature03703","volume":"435","author":"DA Sipkins","year":"2005","unstructured":"Sipkins DA et al (2005) In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 435:969\u2013973","journal-title":"Nature"},{"key":"10412_CR188","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3389\/fimmu.2018.01681","volume":"9","author":"SH Lee","year":"2018","unstructured":"Lee SH et al (2018) Real-time monitoring of cancer cells in live mouse bone marrow. Front Immunol 9:1681","journal-title":"Front Immunol"},{"key":"10412_CR189","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.orthres.2005.02.013","volume":"23","author":"N Hansen-Algenstaedt","year":"2005","unstructured":"Hansen-Algenstaedt N et al (2005) Femur window\u2014a new approach to microcirculation of living bone in situ. J Orthop Res 23:1073\u20131082","journal-title":"J Orthop Res"},{"key":"10412_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060176","volume":"10","author":"AH Jinnah","year":"2018","unstructured":"Jinnah AH, Zacks BC, Gwam CU, Kerr BA (2018) Emerging and established models of bone metastasis. Cancers 10:176","journal-title":"Cancers"},{"key":"10412_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-618","volume":"14","author":"X Zhou","year":"2014","unstructured":"Zhou X, Liu J (2014) A computational model to predict bone metastasis in breast cancer by integrating the dysregulated pathways. BMC Cancer 14:618","journal-title":"BMC Cancer"},{"key":"10412_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/npjbcancer.2015.18","volume":"1","author":"PK Newton","year":"2015","unstructured":"Newton PK et al (2015) Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. npj Breast Cancer 1:15018","journal-title":"npj Breast Cancer"},{"key":"10412_CR193","doi-asserted-by":"crossref","unstructured":"Li X et al. (2025) Streamlining large-scale genomic data management: Insights from the UK Biobank whole-genome sequencing data. Cell Genomics 5","DOI":"10.1101\/2025.01.27.25321225"},{"key":"10412_CR194","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05402-9","volume":"611","author":"A Ca\u00f1ellas-Socias","year":"2022","unstructured":"Ca\u00f1ellas-Socias A et al (2022) Metastatic recurrence in colorectal cancer arises from residual EMP1+ cells. Nature 611:603\u2013613","journal-title":"Nature"},{"key":"10412_CR195","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-021-03614-z","volume":"594","author":"AL Correia","year":"2021","unstructured":"Correia AL et al (2021) Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. Nature 594:566\u2013571","journal-title":"Nature"},{"key":"10412_CR196","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","volume":"40","author":"A Recasens","year":"2019","unstructured":"Recasens A, Munoz L (2019) Targeting cancer cell dormancy. Trends Pharmacol Sci 40:128\u2013141","journal-title":"Trends Pharmacol Sci"},{"key":"10412_CR197","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-025-02250-9","volume":"24","author":"S Yang","year":"2025","unstructured":"Yang S et al (2025) Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies. Mol Cancer 24:47","journal-title":"Mol Cancer"},{"key":"10412_CR198","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20210836","volume":"219","author":"BD Khalil","year":"2021","unstructured":"Khalil BD et al (2021) An NR2F1-specific agonist suppresses metastasis by inducing cancer cell dormancy. J Exp Med 219:e20210836","journal-title":"J Exp Med"},{"key":"10412_CR199","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s44222-024-00154-9","volume":"2","author":"LNM Nguyen","year":"2024","unstructured":"Nguyen LNM et al (2024) The mechanisms of nanoparticle delivery to solid tumours. Nat Rev Bioeng 2:201\u2013213","journal-title":"Nat Rev Bioeng"},{"key":"10412_CR200","doi-asserted-by":"publisher","first-page":"655781","DOI":"10.3389\/fonc.2021.655781","volume":"11","author":"F Moradi Kashkooli","year":"2021","unstructured":"Moradi Kashkooli F, Soltani M, Momeni MM, Rahmim A (2021) Enhanced drug delivery to solid tumors via drug-loaded nanocarriers: an image-based computational framework. Front Oncol 11:655781","journal-title":"Front Oncol"},{"key":"10412_CR201","doi-asserted-by":"publisher","DOI":"10.1002\/adbi.202500485","volume":"10","author":"Z Sun","year":"2026","unstructured":"Sun Z, Li B, Chen Z, Zhang Z (2026) Dormancy and recurrence in breast cancer bone metastasis: from mechanisms to clinical translation. Adv Biol 10:e00485","journal-title":"Adv Biol"},{"key":"10412_CR202","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","volume":"19","author":"X Lian","year":"2024","unstructured":"Lian X et al (2024) Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat Nanotechnol 19:1409\u20131417","journal-title":"Nat Nanotechnol"},{"key":"10412_CR203","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.apsb.2021.06.012","volume":"12","author":"C Liu","year":"2022","unstructured":"Liu C et al (2022) The osteogenic niche-targeted arsenic nanoparticles prevent colonization of disseminated breast tumor cells in the bone. Acta Pharm Sin B 12:364\u2013377","journal-title":"Acta Pharm Sin B"},{"key":"10412_CR204","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1084\/jem.20110840","volume":"208","author":"A Kobayashi","year":"2011","unstructured":"Kobayashi A et al (2011) Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med 208:2641\u20132655","journal-title":"J Exp Med"},{"key":"10412_CR205","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1593\/neo.91384","volume":"12","author":"Y Shiozawa","year":"2010","unstructured":"Shiozawa Y et al (2010) GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 12:116\u2013127","journal-title":"Neoplasia"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-026-10412-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-026-10412-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:08:33Z","timestamp":1787670513000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-026-10412-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":205,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["10412"],"URL":"https:\/\/doi.org\/10.1007\/s10585-026-10412-2","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"22 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31"}}